Ideaya Biosciences stock hits 52-week low at $19.95

In a challenging year for biotech firms, Ideaya Biosciences Inc . (NASDAQ:IDYA) stock has reached a 52-week low, touching down at $19.95. According to InvestingPro data, analysts maintain a strong bullish consensus with price targets ranging from $27 to $65, suggesting potential upside. The company, known for its precision medicine oncology treatments, has seen a significant downturn over the past year, with a 1-year change showing a steep decline of -57.19%. This latest price level reflects investor concerns and a broader industry trend of risk aversion amidst a volatile market. Despite the current lows, Ideaya continues to advance its targeted therapeutics, maintaining a strong financial position with a healthy current ratio of 14.97 and minimal debt-to-equity of 0.02. InvestingPro subscribers can access 8 additional key insights and a comprehensive research report that provides deeper analysis of IDYA’s financial health and growth prospects.

In other recent news, IDEAYA Biosciences has announced the appointment of Joshua Bleharski, Ph.D., as its new Chief Financial Officer, effective in May 2025. Dr. Bleharski brings a wealth of experience from his previous role at J.P. Morgan, where he was Managing Director and Global Co-Head of Biopharma in the Healthcare Investment Banking group. Additionally, IDEAYA Biosciences has entered into an exclusive licensing agreement with Jiangsu Hengrui Pharma for the development and commercialization of SHR-4849, a drug targeting DLL3 in small cell lung cancer and neuroendocrine solid tumors, outside Greater China. This agreement includes potential payments up to $1.045 billion and royalties on sales.

BTIG analysts have maintained their Buy rating on IDEAYA Biosciences with a price target of $62, citing anticipated pipeline updates as a key factor. These updates include clinical data from studies on darovasertib and IDE397 + Trodelvy, as well as Phase 1 data for the Werner Helicase inhibitor IDE275. RBC Capital also reaffirmed its Outperform rating with a $61 price target, highlighting IDEAYA’s robust precision medicine pipeline and the nomination of new development candidates. Furthermore, IDEAYA has nominated IDE251, a dual inhibitor targeting KAT6 and KAT7, for cancer treatment development, with plans for an IND submission in 2025. These developments reflect IDEAYA’s ongoing efforts to expand its oncology pipeline and advance its precision medicine initiatives.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.